Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.32 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.31 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.31 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1812027 | 0.95 | CYP2C19 (0.50) | CYP2C19KDM1ACYP4F2CYP4A11FFAR3 | |
| SCHEMBL19753 | 0.93 | CYP2C19 (0.54) | CYP2C19KDM1ACYP4F2CYP4A11FFAR3 | |
| SCHEMBL27884023 | 0.91 | CYP2C19 (0.38) | CYP2C19KDM1ACYP4F2CYP4A11FFAR3 | |
| SCHEMBL1173680 | 0.91 | — | — | |
| SCHEMBL19216525 | 0.84 | CYP2C19 (0.39) | CYP2C19KDM1ACYP4F2CYP4A11 | |
| SCHEMBL25477600 | 0.82 | CYP4F2 (0.39) | CYP2C19CYP4F2CYP4A11DGAT1 | |
| SCHEMBL15116437 | 0.82 | CYP4F2 (0.35) | CYP2C19CYP4F2CYP4A11 | |
| SCHEMBL17960538 | 0.81 | DGAT1 (0.34) | CYP2C19CYP4F2CYP4A11FFAR3DGAT1 | |
| SCHEMBL15105794 | 0.81 | CYP2C19 (0.32) | CYP2C19FFAR3DGAT1 | |
| SCHEMBL27782501 | 0.81 | OPRM1 (0.35) | CYP2C19FFAR3DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236608-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-07-24 | — | — | US | disclosed |
| US-20250034196-A1 | ESTER DERIVATIVES OF N4-HYDROXYCYTIDINE AND USE THEREOF | SUZHOU SPRING-SEA BIO-PHARMACEUTICALS CO., LTD. (CN) | 2025-01-30 | — | — | US | disclosed |
| EP-4430055-A1 | ESTER DERIVATIVES OF N4-HYDROXYCYTIDINE AND USE THEREOF | Suzhou Spring-Sea Bio-Pharmaceuticals Co., Ltd. (CN) | 2024-09-18 | — | — | EP | disclosed |
| CN-117642410-A | Ester derivatives of N4-hydroxycytidine and uses thereof | 苏州春海生物医药有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-116583530-A | N 4 Ester derivatives of hydroxycytidine and their use | 苏州春海生物医药有限公司 | 2023-08-11 | — | — | CN | disclosed |
| WO-2022262845-A1 | ESTER DERIVATIVES OF N4-HYDROXYCYTIDINE AND USE THEREOF | SUZHOU SPRING-SEA BIO-PHARMACEUTICALS CO., LTD. (CN) | 2022-12-22 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-10040791-B2 | Isoxazole derivative as mutant isocitrate dehydrogenase 1 inhibitor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-08-07 | — | — | US | disclosed |
| US-20170313696-A1 | ISOXAZOLE DERIVATIVE AS MUTANT ISOCITRATE DEHYDROGENASE 1 INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-11-02 | — | — | US | disclosed |
| US-20170313696-A1 | ISOXAZOLE DERIVATIVE AS MUTANT ISOCITRATE DEHYDROGENASE 1 INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-11-02 | — | — | US | disclosed |
| EP-3202766-A1 | ISOXAZOLE DERIVATIVE AS MUTATED ISOCITRATE DEHYDROGENASE 1 INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313696-A1 | ISOXAZOLE DERIVATIVE AS MUTANT ISOCITRATE DEHYDROGENASE 1 INHIBITOR | IDH1, IDH3A, IDH3B | CYP2C19 978/4885KDM1A 45/4885CYP4F2 823/4885 |
| US-10040791-B2 | Isoxazole derivative as mutant isocitrate dehydrogenase 1 inhibitor | IDH1, IDH3A, IDH3B | CYP2C19 978/4885KDM1A 45/4885CYP4F2 823/4885 |
| US-20250236608-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | CYP2C19 3911/4885KDM1A 3495/4885CYP4F2 4382/4885 |
| US-20250034196-A1 | ESTER DERIVATIVES OF N4-HYDROXYCYTIDINE AND USE THEREOF | DCTD, NUDT1, TYMP | CYP2C19 647/4885KDM1A 2075/4885CYP4F2 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.